Recent surveys have revealed that the prevalence of chronic kidney disease (CKD), particularly the hidden mild form (mildly elevated levels of serum creatinine or urinary albumin excretion), is surprisingly high in the general population. In recent years, the global epidemic of type-2 diabetes has led to an alarming increase in the number of patients with CKD. Most patients with CKD (over 50 million individuals worldwide) succumb to cardiovascular events, while each year over 1 million develop end-stage renal failure, which requires costly treatment and in many countries of the world, unaffordable renal replacement therapy by chronic dialysis or renal transplantation [1] .
The diagnosis and management of CKD has been made easier in recent years by the Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines of the US National Kidney Foundation. The K/DOQI guidelines advise that CKD can be defined and appropriately managed by a staging approach that relies on estimating the severity of kidney damage based on the degree of proteinuria and impaired kidney function, the latter assessed as a decrease in the glomerular filtration rate (GFR). CKD is defined as kidney damage for [3 months, with or without decreased GFR, manifested by either pathologic abnormalities or markers of kidney damage such as proteinuria 3.4. If there are no signs of kidney damage, a diagnosis of CKD cannot be made until the GFR is\60 mL/min/1.73 m 2 [2] . Using this standard of measure, the National Kidney Foundation estimates that 20 million Americans have CKD, while an additional 20 million are at risk of the disease [3] .
During this time, an increasing recognition has emerged about the definition and classification limitations, leading to a heated debate and calls for revisions, mainly in nephrology subspecialty journals. The leadership of KDIGO (Kidney Disease: Improving Global Outcomes), with the endorsement of K/DOQI, convened a Controversies Conference to provide a forum for an open discussion on this problem [4] . One important issue was whether or not the current classification (based on eGFR) should be modified to include additional factors associated with prognosis. The conference generated a table similar to the one used for the European Hypertension Guidelines [5] . It was drawn by a composite ranking of relative risks that enhances communication about prognosis in which colours indicate groups of patients at progressively higher risk for the major outcomes. This table (Fig. 1 ) would help clinicians, researchers and public health agencies to describe and prioritise efforts aimed at patients and populations at risk of renal disease.
The main improvement in the table is to add the value of urinary albumin excretion categorised by coined the term microalbuminuria in 1982 to describe an increased urinary albumin excretion not detectable by the usual urinalysis but exceeding 20 lg/min. With this criterion, they differentiated patients with insulindependent diabetes mellitus into those with and those without microalbuminuria and suggested that patients with microalbuminuria might have a worse renal prognosis. Microalbuminuria in patients with diabetes has been recognised not only as a predictor of progression of diabetic nephropathy but also as a powerful independent risk factor for cardiovascular disease [7] [8] [9] . Even in nondiabetic hypertensive patients microalbuminuria has been shown to predict renal and cardiovascular events, and a continuous relation between urinary albumin excretion and cardiovascular, as well as noncardiovascular, mortality has recently been found in a general population study [10] [11] [12] [13] [14] .
A large body of evidence also shows that a greater initial level of proteinuria and an increase over time are independent predictors of both faster GFR decrease and development of kidney failure in patients with wide variety of types of kidney disease [15] . These results appear strong across all segments of the population and all levels of proteinuria, including levels of albuminuria less than the threshold for the definition of CKD. In many studies, proteinuria is associated more strongly with kidney disease outcomes than all other factors tested. Observational studies show a strong relationship between the presence of nephrotic-range proteinuria and increased risk of future GFR decrease irrespective of the cause and pathological state of kidney disease, with the exception of minimal change disease. The risk of progression to kidney failure during 5-10 years is 20-90 % in adults with primary kidney diseases. The same general pattern is observed for patients with nephrotic syndrome caused by systemic diseases. Conversely, complete remission of nephrotic syndrome (to normal urine total protein levels) is associated with a greater likelihood of stability of GFR and freedom from development of kidney failure [16] .
Nevertheless, we think that current table is somewhat cumbersome to use and its use could be improved through an easy simplification. As it can be seen in Fig. 1 , there are four entries for GFR with the same final risk when crossed with the albuminuria range, since prognosis does not change until GFR is below 60 ml/min. This makes it difficult to use the 
